In terms of safety, risks of neuropathy, hospitalizations, and anemia were significantly higher with RVD compared with RD or VD.
Daratumumab and lenalidomide improved survival outcomes over lenalidomide and dexamethasone in frail patients with newly diagnosed MM.
This page includes links to articles highlighting the top gastrointestinal cancer research published on Cancer Therapy Advisor in 2024.
Radiation oncologists report that prior authorization requirements can lead to treatment delays that cause patients to abandon treatment, be hospitalized, become disabled, and even die.
The final analysis of a phase 2 trial confirmed “substantial activity” and prolonged survival in treatment-naïve and previously treated patients with ALK-positive NSCLC, researchers wrote.
Research presented at SABCS 2024 highlighted efforts to expand treatment options for early breast cancer as well as de-escalate treatment.
Patients with a negative colonoscopy result had a “persistently lower” risk of colorectal cancer incidence and death for at least 20 years, researchers found.
Patients with high-risk early breast cancer have similar survival outcomes with different dosing schedules of adjuvant anthracycline- and taxane-based chemotherapy.
Research presented at ASH 2024 could change the treatment of patients with newly diagnosed and relapsed or refractory MM, according to experts.
Research presented at ASH 2024 has shed new light on treatment strategies for mantle cell lymphoma and follicular lymphoma.
Trial results presented at the ASH Annual Meeting 2024 could prompt changes in the treatment of CLL and SLL, experts say.
